Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Obstetrics and Gynecology|November 1, 1980
Combination chemotherapy of advanced ovarian cancer with hexamethylmelamine, cis-Platinum, and doxorubicin after failure of prior therapyS E Vogl, M Pagano, B H Kaplan, et al.
Cancer Treatment Reports|September 1, 1985
Intensive induction treatment of small cell bronchogenic carcinoma with cyclophosphamide, methotrexate, and etoposideP Bonomi, W O'Reilly, S E Vogl, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 26, 2015
Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two casesLucie Bartova, Sonja E Vogl, Mara Stamenkovic, et al.
American Journal of Clinical Oncology|October 1, 1988
Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancerA Y Chang, A Solan, B H Kaplan, et al.
Cancer|August 1, 1985
A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancerS E Vogl, D A Schoenfeld, B H Kaplan, et al.
Cancer Treatment Reports|September 1, 1984
Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579)R H Creech, D Tritchler, D S Ettinger, et al.
Cancer Treatment Reports|June 1, 1982
Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapyS E Vogl, M Pagano, T E Davis, et al.
The Journal of Urology|November 1, 1990
Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology GroupD L Trump, P Elson, S Madajewicz, et al.
Cancer|February 15, 1986
Sequential methotrexate and 5-fluorouracil with bleomycin and cisplatin in the chemotherapy of advanced squamous cancer of the head and neckS E Vogl, A Komisar, B H Kaplan, et al.
Investigational New Drugs|January 1, 1990
A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot studyD L Trump, J C Marsh, L K Kvols, et al.
Pageof 6